Hemodiabsorption in treatment of hepatic failure.
Conducted at the University of California, Los Angeles, this randomized, prospectively controlled study was designed to measure the effects of a hemodiabsorption device in the treatment of 11 patients with hepatic failure and stage III to IV encephalopathy. The results of 5 days of treatment with the hemodiabsorption device were compared with those of standard intensive care procedures. The BioLogic-DT System, a simple sorbent-based system, demonstrated a slight improvement in the neurologic status of patients, a significant improvement in the physiologic status of patients, and an improved outcome for treated patients as opposed to nontreated patients.
Wilkinson
A H
AH
Division of Nephrology, UCLA Medical Center, USA.
Ash
S R
SR
Nissenson
A R
AR
D000328:Adult; D000368:Aged; D003422:Critical Care / Q000379:methods; D005260:Female; D017583:Hemodiafiltration / Q000295:instrumentation / Q000379:methods; D006801:Humans; D017093:Liver Failure / Q000145:classification / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome